Abstract
A phase I study was performed to determine the maximally tolerated dose of carboplatin, ifosfamide, and docetaxel in advanced head and neck cancers. Carboplatin (week 1) was administered with weekly docetaxel and ifosfamide for 3 weeks in an every 4-week cycle. Restaging was done after two cycles, while dose level escalation was done in cohorts of three patients. Fifteen patients (recurrent/metastatic disease, n = 8; bulky locally advanced disease, n = 7) were enrolled. No dose-limiting toxicities were observed. Toxicities included grade 3 neutropenia and anemia (n = 2, each), and grade 2 thrombocytopenia (n = 3). The final level of carboplatin AUC = 6 (week 1) with docetaxel 30 mg/m(2) per week and ifosfamide 1,000 mg/m(2) per week was chosen for further evaluation. This novel regimen of carboplatin with weekly docetaxel and ifosfamide has a favorable toxicity profile and is active in this setting. Phase II study results are awaited.
References
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D M ShinS M Lippman
Mar 17, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P SchöffskiA R Hanauske
Apr 25, 2000·American Journal of Clinical Oncology·J JaninisD Lefantzis
Sep 21, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L SpechtH S Hansen
Apr 3, 2001·Cancer·D M ShinW K Hong
Jan 5, 2002·The New England Journal of Medicine·A ForastiereD Sidransky
Oct 31, 2003·Oncology·M AiroldiC Bumma
Nov 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ricardo HittHernán Cortés-Funes
Dec 6, 2005·Cancer·Ricardo HittHernan Cortes-Funes
Apr 6, 2006·The Laryngoscope·Orlando Guntinas-LichiusBarbara Krug
Jun 17, 2006·Cancer·Francis P WordenUNKNOWN Southwest Oncology Group, Head and Neck Working Group
Oct 26, 2007·The New England Journal of Medicine·Marshall R PosnerUNKNOWN TAX 324 Study Group
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Oct 13, 2010·American Journal of Clinical Oncology·Pol SpecenierJan B Vermorken
Feb 5, 2011·American Journal of Clinical Oncology·Neal E ReadyTeresa Kennedy